P. V. Jenkins

发表

hemophilia A: implications for genetic counseling Analysis of intron 22 inversions of the factor VIII gene in severe

K. Pasi, P. Collins, A. Riddell, 2011 .

Carrier detection and prenatal diagnosis by intron 22 inversion analysis of the factor VIII gene

K. Pasi, P. V. Jenkins, E. Goldman, 1995, Haemophilia : the official journal of the World Federation of Hemophilia.

Analysis of intron 22 inversions of the factor VIII gene in severe hemophilia A: implications for genetic counseling.

K. Pasi, P. Collins, C. Lee, 1994, Blood.

Thrombin generation in haemophilia A patients with mutations causing factor VIII assay discrepancy

C. Gannon, J. O’Donnell, S. Harmon, 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

Laboratory coagulation tests and recombinant porcine factor VIII: A United Kingdom Haemophilia Centre Doctors’ Organisation guideline

A. Riddell, S. Platton, W. Lester, 2022, Haemophilia : the official journal of the World Federation of Hemophilia.

Identification of Type 2 von Willebrand Disease in Previously Diagnosed Type 1 Patients: a Reappraisal Using Phenotypes, Genotypes and Molecular Modelling

S. Perkins, K. Pasi, C. Lee, 2000, Thrombosis and Haemostasis.

Enzymatically oxidized phospholipids restore thrombin generation in coagulation factor deficiencies

S. Lacroix-Desmazes, A. Clayton, M. Heurich, 2018, JCI insight.

Role of P1 residues Arg336 and Arg562 in the activated-Protein-C-catalysed inactivation of Factor VIIIa.

P. Fay, H. Wakabayashi, P. V. Jenkins, 2006, The Biochemical journal.

Concentration-dependent roles for heparin in modifying liopolysaccharide-induced activation of mononuclear cells in whole blood

B. White, R. Preston, J. O'Donnell, 2008, Thrombosis and Haemostasis.

Survival of von Willebrand factor released following DDAVP in a type 1 von Willebrand disease cohort: Influence of glycosylation, proteolysis and gene mutations

J. V. van Mourik, D. Bowen, I. Mackie, 2008, Thrombosis and Haemostasis.

Protamine sulfate down-regulates thrombin generation by inhibiting factor V activation.

P. Fallon, B. White, F. Ní Áinle, 2009, Blood.

Laboratory coagulation tests and emicizumab treatment A United Kingdom Haemophilia Centre Doctors' Organisation guideline

S. Kitchen, A. Riddell, S. Platton, 2019, Haemophilia : the official journal of the World Federation of Hemophilia.

Factor VIII gene inversions in severe hemophilia A: results of an international consortium study.

F E Preston, P G Mori, S S Sommer, 1995, Blood.

A recurrent F8 mutation in Irish haemophilia A patients: evidence for a founder effect

J. O’Donnell, P. V. Jenkins, P. Winter, 2008, Haemophilia : the official journal of the World Federation of Hemophilia.

Laboratory measurement of factor replacement therapies in the treatment of congenital haemophilia: A United Kingdom Haemophilia Centre Doctors’ Organisation guideline

S. Kitchen, A. Riddell, S. Platton, 2019, Haemophilia : the official journal of the World Federation of Hemophilia.

Will the ‘true’ factor level make itself known? Measuring factor therapy for treatment of hemophilia in the era of enhanced half‐life products

P. V. Jenkins, P. Jenkins, 2019, Research and practice in thrombosis and haemostasis.

Clustered basic residues within segment 484–510 of the factor VIIIa A2 subunit contribute to the catalytic efficiency for factor Xa generation

P. Fay, P. V. Jenkins, Q. Zhou, 2004, Journal of thrombosis and haemostasis : JTH.

Factor VIII and von Willebrand factor interaction: biological, clinical and therapeutic importance

J. O’Donnell, V. Terraube, P. Jenkins, 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

Mutating factor VIII: lessons from structure to function.

P. Fay, Philip J Fay, P Vincent Jenkins, 2005, Blood reviews.

Mutation analysis of haemophilia B in the Irish population: increased prevalence caused by founder effect

B. Nolan, B. White, J. O’Donnell, 2008, Haemophilia : the official journal of the World Federation of Hemophilia.

Detection of mutations causing hemophilia a using an in vitro coupled transcription and translation system.

P. V. Jenkins, C. Ononye, 1999, Methods in molecular medicine.

Molecular modeling of ligand and mutation sites of the type A domains of human von Willebrand factor and their relevance to von Willebrand's disease.

S. Perkins, K. Pasi, P. V. Jenkins, 1998, Blood.

Aberrant dimerization of von Willebrand factor as the result of mutations in the carboxy-terminal region: identification of 3 mutations in members of 3 different families with type 2A (phenotype IID) von Willebrand disease.

K. Pasi, F. Hill, M. D. Williams, 2001, Blood.

The effects of the 32‐bp CCR‐5 deletion on HIV transmission and HIV disease progression in individuals with haemophilia

C. Sabin, K. Pasi, C. Lee, 2000, British journal of haematology.

Expresser phenotype determines ABO(H) blood group antigen loading on platelets and von Willebrand factor

R. McGrath, J. O’Donnell, S. Ward, 2020, Scientific Reports.

The effects of the 32-bp CCR-5 deletion on HIV transmission and HIV disease progression in individuals with haemophilia.

C. Sabin, K. Pasi, C. Lee, 2000 .

Type 2M vWD Resulting from a Lysine Deletion within a Four Lysine Residue Repeat in the A1 Loop of von Willebrand Factor

K. Pasi, P. Collins, C. Mazurier, 2000, Thrombosis and Haemostasis.

Contribution of factor VIIIa A2 and A3-C1-C2 subunits to the affinity for factor IXa in factor Xase.

Qian Zhou, P. Fay, Qian Zhou, 2004, Biochemistry.

Complement Regulator Factor H is a Cofactor for Thrombin in both Pro- and Anticoagulant Roles

T. Hughes, M. Heurich, B. Morgan, 2021, bioRxiv.

Use of the collagen‐binding assay for von Willebrand factor  in the analysis of type 2M von Willebrand disease:  a comparison with the ristocetin cofactor assay

Christine A. Lee, A. Riddell, P. V. Jenkins, 2002, British journal of haematology.

Screening for Candidate Mutations Causing von Willebrand's Disease (vWD).

P. V. Jenkins, P. Jenkins, 1999, Methods in molecular medicine.

Homozygous 2bp Deletion in the Human Factor VII Gene: A Non-Lethal Mutation that Is Associated with a Complete Absence of Circulating Factor VII

P. Mannucci, F. Peyvandi, R. Coppola, 2000, Thrombosis and Haemostasis.

Experience of immune tolerance in a carrier of severe haemophilia A with inhibitor development post‐surgery

P. Collins, C. Loran, C. Percy, 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

Mutations associated with hemophilia A in the 558-565 loop of the factor VIIIa A2 subunit alter the catalytic activity of the factor Xase complex.

Qian Zhou, P. Fay, P. V. Jenkins, 2002, Blood.